Physician profile
Nathaina Smith
NPI 1710411400
$1,274.17
in general payments reported to CMS, 2019-2025
10 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $158 · 2021: $56.22 · 2022: $162 · 2023: $309 · 2024: $219 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $665.45 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $338.10 | 2019-2023 | Rybelsus, Ozempic, Tresiba |
| Astellas Pharma US INC | $115.18 | 2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.13 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.73 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.64 | 2021 | |
| Horizon Therapeutics Plc | $15.01 | 2021 | |
| Lilly USA, LLC | $14.83 | 2023 | Mounjaro |
| Janssen Pharmaceuticals, INC | $12.57 | 2021 | |
| Eisai INC. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaina Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.